D59.0
Drug-induced autoimmune hemolytic anemia
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
Medical Intelligence & Overview
Drug-induced autoimmune hemolytic anemia is a rare condition where certain medications trigger the immune system to attack the body's own red blood cells. This leads to hemolysis, a process where these cells are destroyed faster than they can be produced. As a result, individuals may experience anemia, characterized by fatigue and weakness. Understanding this condition is crucial for timely diagnosis and management, especially in patients on medication known to cause this adverse effect.
Causes & Symptoms
Clinical Causes: Use of specific medications such as penicillin, methyldopa, and cephalosporins Certain antibiotics and antimalarial drugs Chemotherapy agents and other drugs that alter immune system function Genetic predispositions that make certain individuals more susceptible Prolonged medication exposure without monitoring
Key Symptoms: Fatigue and weakness Pallor or pale skin Rapid heartbeat or shortness of breath Dark-colored urine indicating hemoglobin breakdown Jaundice, or yellowing of the skin and eyes Enlarged spleen or liver in some cases Fainting or dizziness in severe cases
Diagnostic & Treatment
Diagnosis Path: • Testing for underlying causes of hemolysis and ruling out other forms of anemia
Treatment Protocols: • Alternative medications may be prescribed if necessary, under medical supervision
Clinical Advice & FAQs
Billing Guidance
Is D59.0 a billable ICD-10 code?
Yes, D59.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D59.0?
Clinical documentation must specify the nature of Drug-induced autoimmune hemolytic anemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference